

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2017 April 7; 23(13): 2269-2452





**EDITORIAL**

- 2269 Gastroesophageal reflux disease and morbid obesity: To sleeve or not to sleeve?  
*Rebecchi F, Allaix ME, Patti MG, Schlottmann F, Morino M*

**REVIEW**

- 2276 Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options  
*Divakarla C, Hamman K, Hein N, Yip D*

**MINIREVIEWS**

- 2286 Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma  
*Asgar K, Farooq A, Zulfiqar B, Rashid MU*

**ORIGINAL ARTICLE**

**Basic Study**

- 2294 Disruption of the TWEAK/Fn14 pathway prevents 5-fluorouracil-induced diarrhea in mice  
*Sezaki T, Hirata Y, Hagiwara T, Kawamura YI, Okamura T, Takanashi R, Nakano K, Tamura-Nakano M, Burkly LC, Dohi T*
- 2308 CMA down-regulates p53 expression through degradation of HMGB1 protein to inhibit irradiation-triggered apoptosis in hepatocellular carcinoma  
*Wu JH, Guo JP, Shi J, Wang H, Li LL, Guo B, Liu DX, Cao Q, Yuan ZY*
- 2318 Cullin 4A is associated with epithelial to mesenchymal transition and poor prognosis in perihilar cholangiocarcinoma  
*Zhang TJ, Xue D, Zhang CD, Zhang ZD, Liu QR, Wang JQ*
- 2330 Notch signaling mediated by TGF- $\beta$ /Smad pathway in concanavalin A-induced liver fibrosis in rats  
*Wang Y, Shen RW, Han B, Li Z, Xiong L, Zhang FY, Cong BB, Zhang B*
- 2337 MicroRNA-145 exerts tumor-suppressive and chemo-resistance lowering effects by targeting CD44 in gastric cancer  
*Zeng JF, Ma XQ, Wang LP, Wang W*
- Case Control Study**
- 2346 Predictors for difficult cecal insertion in colonoscopy: The impact of obesity indices  
*Moon SY, Kim BC, Sohn DK, Han KS, Kim B, Hong CW, Park BJ, Ryu KH, Nam JH*

**Retrospective Cohort Study**

- 2355** Impact of interferon-free antiviral therapy on lipid profiles in patients with chronic hepatitis C genotype 1b  
*Endo D, Satoh K, Shimada N, Hokari A, Aizawa Y*

**Retrospective Study**

- 2365** Transition after pediatric liver transplantation - Perceptions of adults, adolescents and parents  
*Junge N, Migal K, Goldschmidt I, Baumann U*
- 2376** Minimally invasive surgery for gastric cancer: A comparison between robotic, laparoscopic and open surgery  
*Parisi A, Reim D, Borghi F, Nguyen NT, Qi F, Coratti A, Cianchi F, Cesari M, Bazzocchi F, Alimoglu O, Gagnière J, Pernazza G, D'Imporzano S, Zhou YB, Azagra JS, Facy O, Brower ST, Jiang ZW, Zang L, Isik A, Gemini A, Trastulli S, Novotny A, Marano A, Liu T, Annecchiarico M, Badii B, Arcuri G, Avanzolini A, Leblebici M, Pezet D, Cao SG, Goergen M, Zhang S, Palazzini G, D'Andrea V, Desiderio J*
- 2385** Clinical implication of FDG uptake of bone marrow on PET/CT in gastric cancer patients with surgical resection  
*Lee JW, Lee MS, Chung IK, Son MW, Cho YS, Lee SM*

**Observational Study**

- 2396** Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis  
*Lee SK, Song MJ, Kim SH, Lee BS, Lee TH, Kang YW, Kim SB, Song IH, Chae HB, Ko SY, Lee JD*
- 2404** Can mean platelet volume play a role in evaluating the severity of acute pancreatitis?  
*Lei JJ, Zhou L, Liu Q, Xiong C, Xu CF*

**Prospective Study**

- 2414** Proposed criteria to differentiate heterogeneous eosinophilic gastrointestinal disorders of the esophagus, including eosinophilic esophageal myositis  
*Sato H, Nakajima N, Takahashi K, Hasegawa G, Mizuno K, Hashimoto S, Ikarashi S, Hayashi K, Honda Y, Yokoyama J, Sato Y, Terai S*
- 2424** Therapeutic experience of 289 elderly patients with biliary diseases  
*Zhang ZM, Liu Z, Liu LM, Zhang C, Yu HW, Wan BJ, Deng H, Zhu MW, Liu ZX, Wei WP, Song MM, Zhao Y*

**META-ANALYSIS**

- 2435** What is the quantitative risk of gastric cancer in the first-degree relatives of patients? A meta-analysis  
*Yaghoobi M, McNabb-Baltar J, Bijarchi R, Hunt RH*

**CASE REPORT**

- 2443** Hepatic angiosarcoma with clinical and histological features of Kasabach-Merritt syndrome  
*Wadhwa S, Kim TH, Lin L, Kanel G, Saito T*

**LETTERS TO THE EDITOR**

**2448** Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma

*Rimassa L, Reig M, Abbadessa G, Peck-Radosavljevic M, Harris W, Zagonel V, Pastorelli D, Rota Caremoli E, Porta C, Damjanov N, Patel H, Daniele B, Lamar M, Schwartz B, Goldberg T, Santoro A, Bruix J*

**ABOUT COVER**

Editorial board member of *World Journal of Gastroenterology*, Piero Luigi Almasio, MD, Associate Professor, Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo 90127, Italy

**AIMS AND SCOPE**

*World Journal of Gastroenterology* (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7<sup>th</sup>, 14<sup>th</sup>, 21<sup>st</sup>, and 28<sup>th</sup> each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

**INDEXING/ABSTRACTING**

*World Journal of Gastroenterology* (*WJG*) is now indexed in Current Contents<sup>®</sup>/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch<sup>®</sup>), Journal Citation Reports<sup>®</sup>, Index Medicus, MEDLINE, PubMed, PubMed Central, Digital Object Identifier, and Directory of Open Access Journals. The 2015 edition of Journal Citation Reports<sup>®</sup> released by Thomson Reuters (ISI) cites the 2015 impact factor for *WJG* as 2.787 (5-year impact factor: 2.848), ranking *WJG* as 38 among 78 journals in gastroenterology and hepatology (quartile in category Q2).

**FLYLEAF**

**I-IX** Editorial Board

**EDITORS FOR THIS ISSUE**

**Responsible Assistant Editor:** *Xiang Li*  
**Responsible Electronic Editor:** *Fen-Fen Zhang*  
**Proofing Editor-in-Chief:** *Lian-Sheng Ma*

**Responsible Science Editor:** *Ze-Mao Gong*  
**Proofing Editorial Office Director:** *Jin-Lei Wang*

**NAME OF JOURNAL**  
*World Journal of Gastroenterology*

**ISSN**  
 ISSN 1007-9327 (print)  
 ISSN 2219-2840 (online)

**LAUNCH DATE**  
 October 1, 1995

**FREQUENCY**  
 Weekly

**EDITORS-IN-CHIEF**  
**Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon**, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

**Stephen C Strom, PhD, Professor**, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

**Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology**, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

**EDITORIAL BOARD MEMBERS**  
 All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

**EDITORIAL OFFICE**  
 Jin-Lei Wang, Director  
 Yuan Qi, Vice Director  
 Ze-Mao Gong, Vice Director  
*World Journal of Gastroenterology*  
 Baishideng Publishing Group Inc  
 8226 Regency Drive,  
 Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
 Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

**PUBLISHER**  
 Baishideng Publishing Group Inc  
 8226 Regency Drive,  
 Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
 Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

**PUBLICATION DATE**  
 April 7, 2017

**COPYRIGHT**  
 © 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
 All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

**INSTRUCTIONS TO AUTHORS**  
 Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

**ONLINE SUBMISSION**  
<http://www.f6publishing.com>

## Observational Study

**Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis**

Soon Kyu Lee, Myeong Jun Song, Seok Hyun Kim, Byung Seok Lee, Tae Hee Lee, Young Woo Kang, Suk Bae Kim, Il Han Song, Hee Bok Chae, Soon Young Ko, Jae Dong Lee

Soon Kyu Lee, Myeong Jun Song, Division of Hepatology, Department of Internal Medicine, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon 34943, South Korea

Seok Hyun Kim, Byung Seok Lee, Department of Internal Medicine, Chungnam University Hospital, Daejeon 35015, South Korea

Tae Hee Lee, Young Woo Kang, Department of Internal Medicine, Konyang University Hospital, Daejeon 35365, South Korea

Suk Bae Kim, Il Han Song, Department of Internal Medicine, Dankook University Hospital, Cheonan 31116, South Korea

Hee Bok Chae, Department of Internal Medicine, ChungBuk University Hospital, Cheongju 28644, South Korea

Soon Young Ko, Jae Dong Lee, Department of Internal Medicine, Konkuk University Chungju Hospital, Chungju 27376, South Korea

**Author contributions:** Lee SK wrote the paper; Song MJ, Kim SH, Lee BS, Lee TH, Kang YW, Kim SB, Song IH, Chae HB, Ko SY and Lee JD collected the data; Song MJ designed the study and analyzed the data.

**Supported by the Catholic Medical Center Research Foundation program in 2014, No. 5-2014-B0001-00176.**

**Institutional review board statement:** Ethics approval was provided by the institutional Ethics Review Board, The Catholic University of Korea (DC15RIMI0008).

**Informed consent statement:** All study participants provided informed written consent about medical data collection prior to study enrollment.

**Conflict-of-interest statement:** The authors declare no conflicts

of interest.

**Data sharing statement:** The original anonymous dataset is available on request from the corresponding author at [mjsong95@gmail.com](mailto:mjsong95@gmail.com).

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** Myeong Jun Song, MD, PhD, Division of Hepatology, Department of Internal Medicine, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daeheung-ro 64, Jung-gu, Daejeon 34943, South Korea. [mjsong95@gmail.com](mailto:mjsong95@gmail.com)  
Telephone: +82-42-2209291

**Received:** January 4, 2017

**Peer-review started:** January 7, 2017

**First decision:** February 9, 2017

**Revised:** February 20, 2017

**Accepted:** March 15, 2017

**Article in press:** March 15, 2017

**Published online:** April 7, 2017

**Abstract****AIM**

To evaluate the safety and efficacy of tenofovir disoproxil fumarate (TDF) as a first-line therapy in

decompensated liver disease.

## METHODS

We enrolled 174 chronic hepatitis B-related liver cirrhosis patients treated with 300 mg/d TDF at six Korean centers. Of the 174 cirrhosis patients, 57 were assigned to the decompensated cirrhosis group and 117 were assigned to the compensated cirrhosis group. We followed the patients for 12 mo and evaluated clinical outcomes, including biochemical, virological, and serological responses. We also evaluated changes in hepatic and renal function and compared the decompensated and compensated cirrhosis groups.

## RESULTS

The 1-year complete virological response (CVR) and Hepatitis B e antigen (HBeAg) seroconversion were seen in 70.2% and 14.2% in the decompensated cirrhosis group, respectively. The rates of HBeAg seroconversion/loss and ALT normalization at month 12 were similar in both groups. TDF treatment was also effective for decreasing the level of hepatitis B virus (HBV) DNA in both groups, but CVR was higher in the compensated group (88.9% *vs* 70.2%,  $P = 0.005$ ). Tenofovir treatment for 12 mo resulted in improved Child-Turcotte-Pugh (CTP) and model for end-stage liver disease (MELD) scores in decompensated group ( $P < 0.001$ ). Of the 57 decompensated patients, 39 (68.4%) achieved CTP class A and 27 (49.1%) showed improvement in the CTP score of 2 points after 12 mo of TDF. The observed rate of confirmed 0.5 mg/dL increases in serum levels of creatinine in the decompensated and compensated cirrhosis group were 7.0% and 2.5%, respectively ( $P < 1.000$ ).

## CONCLUSION

TDF therapy in decompensated cirrhosis patients was effective for decreasing HBV DNA levels and improving hepatic function with relatively lower CVR than in compensated cirrhosis. Thus, physicians should carefully monitor not only renal function but also treatment responses when using TDF in decompensated cirrhosis patients.

**Key words:** Tenofovir; Decompensated liver cirrhosis; Compensated liver cirrhosis; Virological response; Renal safety

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** We evaluated the safety and efficacy of disoproxil fumarate (TDF) treatment in patients with treatment-naïve chronic hepatitis B related decompensated cirrhosis. TDF therapy for 12 mo in decompensated cirrhosis patients was effective for decreasing hepatitis B virus DNA levels and improving hepatic function with relatively lower complete virological response (CVR) than in compensated cirrhosis (70.2% *vs* 88.9%). The elevation of serum creatinine ( $> 0.5$  mg/dL) in the decompensated cirrhosis relatively

higher compared to compensated cirrhosis patients (7.0% *vs* 2.5%, respectively,  $P < 1.000$ ). Therefore, TDF therapy is useful in decompensated cirrhosis and needed for close monitoring of CVR and renal function.

Lee SK, Song MJ, Kim SH, Lee BS, Lee TH, Kang YW, Kim SB, Song IH, Chae HB, Ko SY, Lee JD. Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis. *World J Gastroenterol* 2017; 23(13): 2396-2403 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i13/2396.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i13.2396>

## INTRODUCTION

Chronic hepatitis B virus (CHB) infection is a the major public health problem because of its worldwide distribution and its substantial morbidity, and mortality due to complications of cirrhosis and hepatocellular carcinoma (HCC)<sup>[1]</sup>. In cirrhosis, the 5-year probability of decompensation is 15%-20%, with higher risks associated with high viral replication<sup>[2]</sup>. The 5-year survival rate is 14%-35% for decompensated cirrhosis<sup>[2]</sup>.


Decompensation usually presents with at least one episode of ascites, jaundice, hepatic encephalopathy, or variceal bleeding. Patients with decompensated cirrhosis should be treated with potent nucleos(t)ide analogues (NUCs) with good resistance profiles (*e.g.*, entecavir or tenofovir)<sup>[3,4]</sup>. Treatment is indicated even if hepatitis B virus (HBV) DNA level is low to prevent recurrent reactivation<sup>[3,4]</sup>. However, there is little information on the safety of tenofovir in decompensated cirrhosis. In addition, tenofovir is cleared primarily by the kidneys, and there have been reports of renal impairment, including Fanconi syndrome. Appropriate monitoring and dosing adjustments are recommended for patients with baseline high renal risk, including one or more of the following: decompensated cirrhosis, creatinine clearance  $< 60$  mL/min, poorly controlled hypertension, proteinuria, or uncontrolled diabetes<sup>[3]</sup>.

Currently, there is little information regarding 1-year treatment efficacy and safety with tenofovir in CHB-related decompensated cirrhosis. In Korea, for 48 wk, we evaluated the safety and efficacy of tenofovir disoproxil fumarate (TDF) in patients with decompensated cirrhosis and those with compensated cirrhosis.

## MATERIALS AND METHODS

### Study population

These retrospective cohort analyses were conducted among 180 treatment-naïve patients with CHB-related cirrhosis who were treated with 300 mg/d TDF from January 2013 to January 2014 at six medical centers in Korea. The study was approved by our institutional ethics review board and was conducted in compliance with the Declaration of Helsinki.



**Figure 1** Flow chart of the enrolled participants. CHB: Chronic hepatitis B; TDF: Tenofovir disoproxil fumarate.

Of these patients, 6 (3.3%) were lost to follow-up. There were no hepatic failure-related deaths during the follow-up period. We analyzed data from the remaining 57 patients with decompensated cirrhosis and 117 with compensated cirrhosis who were treated with 300 mg/d TDF for at least 48 wk in the same period (Figure 1). All patients did not take any other antiviral agent except tenofovir during follow-up period.

Eligibility criteria were as follows: confirmed liver cirrhosis based on clinical tests or radiological imaging [ultrasonography (USG) or liver dynamic computed tomography (CT)]<sup>[5]</sup>, serum levels of HBV DNA  $\geq 10^4$  in HBeAg-negative or  $10^5$  copies/mL in HBeAg-positive CHB, alanine aminotransferase (ALT)  $< 10$  times the upper limit of normal (ULN, 40 IU/L), calculated creatinine clearance (eGFR)  $\geq 50$  mL/min, and no evidence of HCC. Exclusion criteria included HCV-positive serologies; prior oral NUC use, including lamivudine, telbivudine, adefovir, or entecavir; current grade 2 or higher hepatic encephalopathy; history of variceal bleeding within 2 mo; and hepatorenal syndrome or use of hepatotoxic or nephrotoxic drugs, including those affecting renal tubular secretion.

Decompensated cirrhosis was defined as a Child-Turcotte-Pugh (CTP) score  $\geq 7$  (Child B and C) or at least one episode of ascites, jaundice, hepatic encephalopathy, or variceal bleeding.

#### Follow-up evaluation

All patients were monitored at least every 3 mo during the antiviral treatment period. Biochemical (serum AST, ALT) and virological parameters (HBeAg, HBeAb status, and quantitative HBV DNA) were assessed at every visit. Imaging studies with USG or liver dynamic CT were performed at every 6 mo. Renal safety in TDF-treated patients was also evaluated in terms of serum levels of creatinine and eGFR every 3 mo.

#### Treatment-efficacy analyses

The primary efficacy endpoints were biochemical,

virological, and serological responses during 48 wk of antiviral treatment. Biochemical response was defined as a normalized ALT ( $\leq 1$  times ULN). Complete virological response (CVR) was defined as a decline in HBV-DNA levels to  $< 116$  copies/mL. Serum HBV DNA was measured using the Roche COBAS TaqMan assay (lower limit of quantification of 116 copies/mL). Selected secondary efficacy end points included the difference between compensated and decompensated cirrhosis in biochemical, virological, and serological responses during 48 wk of antiviral treatment. The mean values of HBV DNA were calculated at baseline, week 12, and at 12-wk intervals through week 48. The incidence of virological breakthrough (confirmed  $\geq 1 \log_{10}$  increase in HBV DNA level from nadir) and cumulative probability of HBV antiviral drug resistance were determined through week 48.

Serological response was defined as the disappearance of HBeAg positivity (HBeAg loss) and then HBeAb positivity (HBeAg seroconversion). Serum HBeAg and HBeAb were measured with a radioimmunoassay (RIA) according to the manufacturer's protocol (Abbott Laboratories, Chicago, IL, United States).

#### Safety analyses

Cumulative safety was assessed through week 48. HBV-related outcomes, including ALT flares, hepatic decompensation, and HCC, were also assessed. The occurrences of serious adverse events and deaths were reported for all enrolled patients. Serum levels of creatinine and creatinine clearance (eGFR using CKD-EPI) were evaluated as categorical end points (confirmed serum levels of creatinine increase from baseline  $\geq 0.5$  mg/dL and creatinine clearance  $< 50$  mL/min) and creatinine was evaluated as a continuous variable.


#### Statistical analysis

Continuous variables are expressed as mean  $\pm$  SD. Serum HBV DNA levels were expressed on

**Table 1** Baseline characteristics of the compensated and decompensated liver cirrhosis groups

	All ( <i>n</i> = 174)	Compensated LC ( <i>n</i> = 117)	Decompensated LC ( <i>n</i> = 57)	<i>P</i> value
Male/female	114/60	73/44	41/16	0.238
Age (yr)	52.2 ± 11.0	52.3 ± 11.0	51.9 ± 11.0	0.889
HBeAg positive	78/96 (44.8%)	50/67 (42.7%)	28/29 (49.1%)	0.516
HBV DNA (log <sub>10</sub> copies/mL)	6.49 ± 1.40	6.34 ± 1.40	6.79 ± 1.35	0.065
ALT (IU/L)	92.8 ± 165.6	77.2 ± 115.2	124.4 ± 235.5	0.014
TB (mg/dL)	1.71 ± 2.40	1.06 ± 0.97	3.04 ± 3.61	0.000
PT INR	1.27 ± 0.29	1.14 ± 0.12	1.49 ± 0.36	0.000
Albumin (g/dL)	3.9 ± 2.95	4.35 ± 3.51	3.03 ± 0.66	0.000
Platelet count (10 <sup>3</sup> /μL)	115.0 ± 48.5	127.7 ± 47.4	90.9 ± 41.1	0.000
Child score	6.1 ± 1.6	5.2 ± 0.5	8.0 ± 1.5	0.000
MELD score	10.1 ± 4.0	8.3 ± 1.87	13.4 ± 4.76	0.000
Ascites			20	
Episode of HE			1	
Episode of varix bleeding			4	

LC: Liver cirrhosis.



**Figure 2** The mean changes in serum HBV DNA levels of the decompensated and compensated cirrhosis group. There were no significant differences in the reduction of serum HBV DNA levels between two groups (*P* = 0.310). LC: Liver cirrhosis.

a logarithmic scale. Between group comparisons were performed using Student *t* test or the Mann-Whitney *U* test for continuous variables, and the  $\chi^2$  test or Fisher's exact test for categorized variables, as appropriate. The multivariate analysis using a logistic regression model was used to determine predictive factors for CVR among various variables including age, pretreatment ALT levels, and viral status. A *P* value of < 0.05 was considered to be significant (SPSS 17, Chicago, IL, United States).

## RESULTS

### Clinical characteristics of the patients

In total, 174 patients were examined in this study from January, 2013 to January 2014. Of these patients, 57 were assigned to the decompensated cirrhosis group and 117 to the compensated cirrhosis group. The baseline characteristics of the two groups are shown in Table 1. The mean age was 52 years old and 65.5% of the patients were males. Mean serum levels of ALT were higher in the decompensated cirrhosis than compensated cirrhosis group (124.4 IU/L vs 77.2

IU/L, *P* = 0.014). The proportion of HBeAg positivity was similar in both groups (42.7% vs 49.1%, *P* = 0.516). The decompensated group had higher CTP and MELD scores, hepatic function (total bilirubin, albumin, PT INR), and platelet counts (*P* < 0.001 for all). In the decompensated cirrhosis group, 20 (35.0%) patients had ascites, 1 (1.7%) had episodes of hepatic encephalopathy, and 4 (7.0%) experienced variceal bleeding.

### Virological, biochemical and serological responses

Virological, serological, and biochemical responses are presented in Table 2. Overall, TDF treatment over 12 mo resulted in a progressive reduction in serum levels of HBV DNA (-4.07 log<sub>10</sub> copies/mL at 6 mo, and -4.30 log<sub>10</sub> copies/mL at 12 mo).

Moreover, undetectable HBV DNA levels were observed in 144 of 174 (82.8%) patients during the 12 mo of TDF treatment. The mean reductions in HBV DNA levels at 6 and 12 mo did not significantly differ between the groups (*P* = 0.31; Figure 2). However, there was a significant difference in CVR; it was higher in the compensated group (88.9% vs 70.2%, *P* = 0.005). There was no virological breakthrough in any patient during the follow-up period. Regarding the biochemical response, ALT normalization was similar between the groups after 12 mo of TDF therapy (77.2% vs 65.8%, *P* = 0.161).

Of the 78 HBeAg-positive patients, 6 (7.7%) and 7 (8.9%) exhibited HBeAg seroconversion at months 6 and 12, respectively, with similar proportions being observed in each group (10.7% vs 6% at 6 mo, *P* = 0.664, and 14.2% vs 6% at 12 mo, *P* = 0.373). This distribution was consistent with the HBeAg loss (0% vs 4% at 6 mo, *P* = 0.427; and 0% vs 4% at 12 mo, *P* = 0.517). Subgroup analyses according to HBeAg status showed that CVR in HBeAg-positive patients were significantly lower in the decompensated group (*P* = 0.01, Table 3). During 12 mo of TDF therapy, the cumulative rate of CVR was significantly higher in HBeAg-negative than in HBeAg-positive patients

**Table 2** Virological, serological and biochemical response after 12 mo of tenofovir disoproxil fumarate therapy *n* (%)

	All ( <i>n</i> = 174)	Compensated LC ( <i>n</i> = 117)	Decompensated LC ( <i>n</i> = 57)	<i>P</i> value
Virological response				
Change in serum HBV DNA level				
Month 6	-4.07 ± 1.39	-4.00 ± 1.42	-4.20 ± 1.32	0.581
Month 12	-4.30 ± 1.38	-4.20 ± 1.39	-4.49 ± 1.35	0.310
Serum HBV DNA undetectable <sup>1</sup>				
Month 6	96 (55.2)	67 (57.3)	29 (50.9)	0.516
Month 12	144 (82.8)	104 (88.9)	40 (70.2)	0.005
Serological				
HBeAg seroconversion				
Month 6	6/78 (7.7)	3/50 (6.0)	3/28 (10.7)	0.664
Month 12	7/78 (8.9)	3/50 (6.0)	4/28 (14.2)	0.373
HBeAg loss				
Month 6	2/78 (2.5)	2 (4.0)	0 (0)	0.427
Month 12	2/78 (2.5)	2 (4.0)	0 (0)	0.517
Biochemical				
ALT normalization				
Month 6	108 (62.0)	72 (61.5)	36 (63.2)	0.869
Month 12	121 (69.5)	77 (65.8)	44 (77.2)	0.161

<sup>1</sup>HBV DNA < 116 copies/mL. LC: Liver cirrhosis. HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen.

**Table 3** Virological response after 12 mo of tenofovir disoproxil fumarate therapy according to HBeAg status *n* (%)

	All	Compensated LC ( <i>n</i> = 50)	Decompensated LC ( <i>n</i> = 28)	<i>P</i> value
Virological response of HBeAg positive patients ( <i>n</i> = 78)				
Change in serum HBV DNA level				
Month 6	-4.32 ± 1.33	-2.89	-3.18	0.926
Month 12	-4.65 ± 1.33	-4.56 ± 1.45	-4.82 ± 1.08	0.701
Serum HBV DNA undetectable				
Month 6	31 (39.7)	20/50 (40)	11/17(39.2)	1.000
Month 12	54 (74.3)	40/10(80)	14/14(50)	0.010
		Compensated LC ( <i>n</i> = 67)	Decompensated LC ( <i>n</i> = 29)	
Virological response of HBeAg negative patients ( <i>n</i> = 96)				
Change in serum HBV DNA level				
Month 6	-3.86 ± 1.40	-3.78 ± 1.39	-4.04 ± 1.43	0.576
Month 12	-4.01 ± 1.37	-3.94 ± 1.30	-4.19 ± 1.51	0.534
Serum HBV DNA undetectable				
Month 6	65 (67.7)	47/20 (70.1)	18/11 (62.0)	0.481
Month 12	90 (93.7)	64/3 (95.5)	26/3 (89.6)	0.362

LC: Liver cirrhosis. HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen.

(93.7% vs 74.3%, *P* < 0.001).

Logistic regression analyses with adjustments for potential baseline confounders (age, sex, HBeAg status, initial HBV DNA levels, and categories of liver disease) showed that baseline HBeAg seropositivity and decompensated liver disease status were the only independent predictive factors that adversely affected CVR during TDF therapy (OR = 5.617, 95%CI: 2.011-15.689, *P* = 0.001, OR = 0.340; 95%CI: 0.139-0.829, *P* = 0.018, respectively; Table 4).

#### Changes in hepatic function after 12 mo of TDF therapy in the decompensated group

To evaluate the influence of TDF therapy on hepatic function reserve in the decompensated group, we measured the CTP and MELD score and compared

these values of pre- and post-treatment (Figure 3). For all 57 patients, the mean CTP score (8.0 vs 6.3), and MELD score (13.4 vs 10.5) improved after 12 mo of TDF treatment vs baseline (all *P* < 0.001). Of them, 27 (49.1%) patients showed an improvement of ≥ 2 points in CTP score. Of the remaining 30 (50.9%) patients, 12 achieved CTP class A with a 1-point of improvement; 4 did not achieve CTP class A despite 1 point in improvement; 11 showed no change, and 3 experienced aggravation. As a result, 39 of the 57 (68.4%) patients achieved CTP class A (score 5 or 6) after 12 mo of TDF.

#### Safety

Changes of creatinine clearance (eGFR) during TDF therapy are shown in Figure 4 and Table 5. There were

**Table 4** Multivariate analysis for complete virological response after 12 mo of tenofovir disoproxil fumarate therapy

	Regression coefficient	Standard error	OR (95%CI)	P value
Age (per year)	-0.018	0.022	0.982 (0.941-1.025)	0.412
Sex	0.427	0.543	1.533 (0.529-4.439)	0.431
ALT level (per 1 IU/L)	0.001	0.001	1.001 (0.999-1.003)	0.342
HBeAg	1.726	0.524	5.617 (2.011-15.689)	0.001
Positivity				
Negativity				
Baseline HBV DNA (per 1 log <sub>10</sub> copies/mL)	0.117	0.184	1.124 (0.784-1.611)	0.525
Diagnosis	-1.080	0.456	0.340 (0.139-0.829)	0.018
Compensated				
Decompensated				

**Table 5** Changes of creatinine clearance (eGFR) during tenofovir disoproxil fumarate therapy for 12 mo

	All (n = 174)	Mean eGFR (CKD-EPI equation)		P value
		Compensated LC (n = 117)	Decompensated LC (n = 57)	
Baseline	95.2 ± 17.8	95.4 ± 14.8	94.8 ± 23.0	0.880
Week 12	91.1 ± 16.2	93.2 ± 13.0	86.6 ± 21.1	0.205
Week 24	91.1 ± 17.5	92.2 ± 14.2	89.2 ± 22.0	0.895
Week 36	90.6 ± 16.6	91.1 ± 14.4	89.7 ± 20.3	0.943
Week 48	90.7 ± 18.4	91.6 ± 14.9	88.9 ± 23.8	0.959

LC: Liver cirrhosis.

no statistically significant differences in eGFR between the groups during TDF therapy. Seven patients (three in the compensated vs four in the decompensated group, 2.5% vs 7.0%,  $P < 1.000$ , respectively) had confirmed  $\geq 0.5$  mg/dL increases from baseline in serum levels of creatinine (all also had confirmed  $CL_{Cr} < 50$  mL/min). Of these seven patients, two patients had increased creatinine at 12 wk, one had it at 24 wk, and four had it at 48 wk.

## DISCUSSION

We examined the safety and efficacy of TDF for 48 wk in treatment-naïve decompensated cirrhosis patients compared to compensated patients. We found that TDF was effective both groups. Moreover, TDF monotherapy significantly improved underlying liver function. Previous studies have shown that entecavir is also effective for decompensated cirrhosis and improves liver function<sup>[6]</sup>. However, the long-term treatment efficacy and safety of TDF in decompensated cirrhosis has not been well established.


In our study, the HBeAg seroconversion rate and the HBeAg loss rate were similar between the groups but were considerably lower than in a previous Liaw's study<sup>[7]</sup>. That study was a phase 2, multi-center, randomized trial conducted at several hospitals in Europe, Canada, Singapore, Taiwan, and the United States. However, our study represented real-world data from Korea. The differences may also be due to the high prevalence of the HBV genotype C, acquired through

vertical transmission.


HBV DNA levels after TDF treatment over 12 mo markedly decreased in both the compensated and decompensated groups. CVR after 12 mo was 70.2% in the decompensated cirrhosis patients, significantly lower than in the compensated group (88.9%,  $P = 0.005$ ). The rate of DNA negativity in the former group was similar to a previous report<sup>[7]</sup>. Moreover, logistic regression analyses showed that baseline HBeAg seropositivity and decompensated cirrhosis were independent predictive factors adversely affecting CVR. No studies to date have compared decompensated and compensated groups treated with TDF. The entecavir study reported by Shim *et al*<sup>[6]</sup> showed no significant difference in HBV DNA negativity between compensated and decompensated cirrhosis patients. The lower CVR in the decompensated group of our study than in the entecavir study may be due to the higher baseline MELD score. Moreover, the stricter cut-off level (HBV-DNA level  $< 116$  copies/mL) could also have contributed to this result. However, even considering these factors, the lower CVR in the decompensated group suggests that there would be a higher risk of hepatic events and mortality in such patients, because entecavir-treated cirrhosis patients without CVR have a higher risk of hepatic events and mortality than CVR patients<sup>[8]</sup>. Moreover, patients without CVR show comparable risks of hepatic events and mortality to untreated patients<sup>[8]</sup>. Thus, we should follow HBV DNA levels more carefully in TDF-treated decompensated patients and check for possible hepatic events more frequently in patients without CVR.

We also measured changes of CTP and MELD scores in the decompensated group to evaluate the effects of TDF on hepatic function. All patients in that group showed improvements in the mean CTP and MELD scores. Moreover, 49.1% of patients had an improvement of  $\geq 2$  points in CTP score and 68.4% of patients achieved CTP class A. This result is similar several previous studies<sup>[9,10]</sup>. Here we showed that TDF therapy not only decreased the HBV DNA level effectively but also improved the hepatic function in the decompensated group.

In terms of renal function, TDF therapy was safe in both groups, consistent with some previous studies<sup>[10,11]</sup>.



**Figure 3** The changes of the Child-Turcotte-Pugh and model for end-stage liver disease scores in the decompensated group after tenofovir disoproxil fumarate treatment for 12 mo. The mean Child-Turcotte-Pugh (CTP) score ( $8.0 \pm 1.5$  vs  $6.3 \pm 1.3$ ) and model for end-stage liver disease (MELD) scores ( $13.4 \pm 4.7$  vs  $10.5 \pm 3.9$ ) improved after 12 mo of tenofovir disoproxil fumarate treatment than at baseline ( $P < 0.001$  for all). CTP: Child-Turcotte-Pugh; MELD: Model for End-stage Liver Disease.



**Figure 4** The changes of creatinine clearance (eGFR) during the tenofovir disoproxil fumarate therapy. Of seven patients with increased serum creatinine more than 0.5 mg/dL, three were in compensated group and four were in decompensated group (2.5% vs 7.0%,  $P < 1.000$ ). There were no statistically significant differences in the changes of creatinine clearance between the decompensated and the compensated group during treatment. LC: Liver cirrhosis.

However, Tsai *et al.*<sup>[12]</sup> reported that TDF is an independent predictor of renal dysfunction and the AASLD guidelines recommend follow-up of renal function in patients after TDF treatment<sup>[4]</sup>. In our study, the decompensated group showed a higher rate of decreasing renal function (7.0% vs 2.5%) but the difference was not statistically significant. Thus, we should be cautious about TDF therapy, particularly in high-risk groups for renal dysfunction, such as patients with uncontrolled diabetes, proteinuria, and poorly controlled hypertension<sup>[3]</sup>. Recently, tenofovir alafenamide (TAF) was introduced as an effective and safe drug<sup>[13-15]</sup>. TAF therapy can be safe and effective for groups at high risk for renal dysfunction. In the future, a TAF study in decompensated cirrhosis patients is needed.

This study had several limitations. First, the study was retrospective design and the patient number was small, thus a prospective study is needed. Second, the follow up period was 1 year, which was sufficient, but data from a longer follow-up period are needed.

In conclusion, we showed that TDF therapy in

decompensated cirrhosis patients was effective for decreasing HBV DNA levels and improving hepatic function with relatively lower CVR than in compensated cirrhosis. Thus, physicians should carefully monitor not only renal function but also treatment responses when using TDF in decompensated cirrhosis patients.

## COMMENTS

### Background

Currently, there is little information regarding 1-year treatment efficacy and safety with tenofovir in chronic hepatitis B virus-related decompensated cirrhosis.

### Innovations and breakthroughs

Authors aim to evaluate the safety and efficacy of tenofovir disoproxil fumarate (TDF) as a first-line therapy in decompensated liver disease.

### Applications

TDF therapy in decompensated cirrhosis patients was effective for decreasing hepatitis B virus DNA levels and improving hepatic function with relatively lower complete virological response than in compensated cirrhosis. Thus, physicians should carefully monitor not only renal function but also treatment responses when using TDF in decompensated cirrhosis patients.

### Peer-review

Overall, this is a clear and well-written manuscript. The introduction is relevant and theory based. The methods are appropriate and the results are clear. The authors make contribution to the research literature in this area of investigation.

## REFERENCES

- 1 **Fattovich G.** Natural history and prognosis of hepatitis B. *Semin Liver Dis* 2003; **23**: 47-58 [PMID: 12616450 DOI: 10.1055/s-2003-37590]
- 2 **Fattovich G, Bortolotti F, Donato F.** Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. *J Hepatol* 2008; **48**: 335-352 [PMID: 18096267 DOI: 10.1016/j.jhep.2007.11.011]
- 3 **EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.** *J Hepatol* 2012; **57**: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]
- 4 **Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH.** AASLD guidelines for treatment of chronic hepatitis B.

- Hepatology* 2016; **63**: 261-283 [PMID: 26566064 DOI: 10.1002/hep.28156]
- 5 **Bruix J**, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology* 2011; **53**: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]
  - 6 **Shim JH**, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. *J Hepatol* 2010; **52**: 176-182 [PMID: 20006394 DOI: 10.1016/j.jhep.2009.11.007]
  - 7 **Liaw YF**, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, Horban A, Wang C, Kwan P, Buti M, Prieto M, Berg T, Kitrinis K, Peschell K, Mondou E, Frederick D, Rousseau F, Schiff ER. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. *Hepatology* 2011; **53**: 62-72 [PMID: 21254162 DOI: 10.1002/hep.23952]
  - 8 **Wong GL**, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, Chan HY, Wong VW. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. *Hepatology* 2013; **58**: 1537-1547 [PMID: 23389810 DOI: 10.1002/hep.26301]
  - 9 **Köklü S**, Tuna Y, Gülşen MT, Demir M, Köksal AŞ, Koçkar MC, Aygün C, Coban S, Ozdil K, Ataseven H, Akin E, Pürnak T, Yüksel I, Ataseven H, Ibiş M, Yildirim B, Nadir I, Küçükazman M, Akbal E, Yüksel O, Başar O, Alkan E, Baykal O. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. *Clin Gastroenterol Hepatol* 2013; **11**: 88-94 [PMID: 23063679 DOI: 10.1016/j.cgh.2012.10.003]
  - 10 **Miquel M**, Núñez Ó, Trapero-Marugán M, Díaz-Sánchez A, Jiménez M, Arenas J, Canós AP. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. *Ann Hepatol* 2013; **12**: 205-212 [PMID: 23396731]
  - 11 **Cholongitas E**, Papatheodoridis GV, Goulis J, Vlachogiannakos J, Karatapanis S, Ketikoglou J, Vasiliadis T, Kontos G, Karlaftis A, Akriviadis E. The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis. *Ann Gastroenterol* 2015; **28**: 109-117 [PMID: 25608681]
  - 12 **Tsai MC**, Chen CH, Tseng PL, Hung CH, Chiu KW, Wang JH, Lu SN, Lee CM, Chang KC, Yen YH, Lin MT, Chou YP, Hu TH. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. *Clin Microbiol Infect* 2016; **22**: 95.e1-95.e7 [PMID: 26055419 DOI: 10.1016/j.cmi.2015.05.035]
  - 13 **Lin CL**, Yang HC, Kao JH. Hepatitis B virus: new therapeutic perspectives. *Liver Int* 2016; **36** Suppl 1: 85-92 [PMID: 26725903 DOI: 10.1111/liv.13003]
  - 14 **Bam RA**, Yant SR, Cihlar T. Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. *Antivir Ther* 2014; **19**: 687-692 [PMID: 24699134 DOI: 10.3851/imp2770]
  - 15 **Agarwal K**, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, Flaherty JF, Lawson E, Zhao S, Subramanian GM, McHutchison JG, Gane EJ, Foster GR. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. *J Hepatol* 2015; **62**: 533-540 [PMID: 25450717 DOI: 10.1016/j.jhep.2014.10.035]

**P- Reviewer:** Fimmel CJ, Gao ZL, Li J, Utku AC, Wang X

**S- Editor:** Yu J **L- Editor:** A **E- Editor:** Wang CH





Published by **Baishideng Publishing Group Inc**  
8226 Regency Drive, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgooffice@wjgnet.com](mailto:bpgooffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>



ISSN 1007-9327



9 771007 932045